Skip to content
MarketScale
‹ Back to IndustriesSciences

FDA SHIFTS TO CFU LABELING FOR SUPPLEMENTS, STILL COMES UP SHORT ACCORDING TO EXPERTS

In September 2018, the FDA issued a draft guidance on how to label supplements containing live microbials. The announcement presents the organization’s “intent to exercise enforcement discretion to allow supplement companies to use colony forming units (CFUs) when declaring the quantity of live microbials on a Supplement Facts Label.”  Why the Guidance Was Issued The new guidance…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Promoted Content · Promoted Content
Share
FDA SHIFTS TO CFU LABELING FOR SUPPLEMENTS, STILL COMES UP SHORT ACCORDING TO EXPERTS

Key takeaways

01

In September 2018, the FDA issued a draft guidance on how to label supplements containing live microbials.

02

The announcement presents the organization’s “intent to exercise enforcement discretion to allow supplement companies to use colony forming units (CFUs) when declaring the quantity of live microbials on a Supplement Facts Label.”  Why the Guidance Was Issued The new guidance…

In September 2018, the FDA issued a draft guidance on how to label supplements containing live microbials. The announcement presents the organization’s “intent to exercise enforcement discretion to allow supplement companies to use colony forming units (CFUs) when declaring the quantity of live microbials on a Supplement Facts Label.”

 Why the Guidance Was Issued

The new guidance comes in response to a widespread disagreement over the use of the weight of ingredients versus colony forming units (CFUs). The new guidance does allow manufacturers to incorporate CFUs; however, weight must still be included on the label, and listed in order of predominance by mass quantity.

Despite the fact that the FDA believes “CFUs provide a useful description of the quantity of live microbial dietary ingredients,” it rejected a petition from the International Probiotics Association to list ingredients only by CFUs rather than weight. While disappointed that the FDA denied the petition, the IPA still considers the new guidance a victory in promoting the use of CFUs. Although weight, which has proven to be an inaccurate way to measure microbials, will continue to be a requirement, the addition of CFUs in live microbial labeling provides consumers with more information to choose the best product for them.

FDA Will Allow CFU Labeling, But Supplements Must Meet 7 Requirements

 The FDA will permit CFU labeling of microbial dietary ingredients provided the following requirements are met:

  1. The quantity is first listed in terms of weight.
  2. The declaration of quantity in CFUs is expressed in a manner that is clearly separate and readily distinguishable from the weight, e.g., as a parenthetical or in a subset line.
  3. The declaration of the quantity in CFUs is formatted in clear terms that can easily be understood by a common reader, e.g., 10 billion or 300* (where the unit that “*” is intended to represent is a typical measurement of CFUs, and is clearly indicated elsewhere in the Supplement Facts label).
  4. The declaration of quantity in CFUs is accurate and not misleading, does not render misleading other aspects of the Supplement Facts label, or other aspects of the product label.
  5. The declaration of quantity in CFUs measures only live microbial ingredients and does not include inactive, dead, or nonviable organisms.
  6. Live microbial dietary ingredients in a proprietary blend are listed in descending order of predominance by weight; and
  7. The product label otherwise complies with all applicable laws and regulations.

 Scientists Prefer CFUs to Measure Live Microbials

CFUs are the scientifically accepted unit of measurement for probiotics. Rather than painstakingly counting every cell individually under a microscope, scientists dilute a sample of microbes and spread it across a Petri plate, allowing them to count groups of microbes, called colonies, with the naked eye. However, each CFU doesn’t necessarily correspond to a single microbe. But if the cells stick together in lumps or chains, the CFU instead refers to these groupings. Each colony is assumed to have grown from a single colony-forming unit, or CFU.

 CRN Commends Guidance but Has Reservations

Another group advocating for CFU usage is the Council for Responsible Nutrition (CRN), the leading trade association for the dietary supplement and functional food industry. While the news of the draft guidance was indeed hopeful, they worry it doesn’t go far enough. Like the IPA, CRN’s main concern is that weight, which must still be included in labeling, isn’t an accurate measurement for determining live microbial counts in products.

CRN thinks the FDA is heading in the right direction but cautions that a “dual listing of ingredient quantity in weight and CFUs presents conflicting product labeling information and puts responsible industry members in an untenable position.”

Why This Matters to Supplement Companies

 At present, the FDA is garnering much feedback on their draft guidance, opinions which may alter their current stance that weight must be included in supplement labeling. Deerland Probiotics & Enzymes wants to ensure that the industry stays abreast of regulatory changes. By subscribing to our blog, Digestible, you can remain current with market trends and regulatory developments that affect how the supplements you sell must be labeled, and the best way to communicate any changes with your customers.

Lear more at deerlandenzymes.com

About the author

PC
Promoted Content

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

PC
Promoted Content

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512